Perinatal infection resident survival guide: Difference between revisions

Jump to navigation Jump to search
 
(24 intermediate revisions by the same user not shown)
Line 23: Line 23:
<br />
<br />
==Overview==
==Overview==
This section provides a short and straight to the point overview of the disease or symptom. The first sentence of the overview must contain the name of the disease.
Most of the [[perinatal]] [[infections]] in the [[neonate]] are [[bacterial]]. These [[infections]] may be acquired from the mother prior to or at birth or from environmental sources. [[Premature]] babies are prone to [[perinatal infections]]. [[Neonates]], especially those born [[Premature|prematurely]] have very limited ability to express symptoms, so, even minor deviations from normal behaviour should suggest [[bacterial]] disease. Chronic [[congenital]] and [[perinatal infections]] are usually asymptomatic in mother and [[neonate]] and may remain latent or sub-clinically active in host tissue for prolonged time.It may cause insidious injury to the central nervous and perceptual systems. When noticeable, these infections almost invariably cause mental or perceptual handicaps or both. [[Cytomegalovirus]] is the most common cause of [[congenital]] infections and the [[Fetus|fetal]] effects of primary [[maternal]] [[infection]] during [[gestation]] can be devastating.[[Perinatal infection]] occurring in the 1st few days to 14 days occurs due to contact with the pathogens present in the cervico-vaginal canal during [[delivery]]. causes are [[Escherichia coli]], [[Group B Streptococcus|Group B beta haemolytic Streptococci,]][[Gonococcal Infections|Gonococci]], [[Listeria monocytogenes]] ,[[Bacteroides]] species, [[Candida albicans]], [[Cytomegalovirus|Cytomegalo virus]],[[Herpes simplex virus|Herpes Simplex Virus]] Type-2.The mortality and morbidity associated with either acute or chronic infections is quite high. So, appropriate diagnosis and treatment is required and should be aggressive.


==Causes==
==Causes==
Line 75: Line 75:


==Diagnosis==
==Diagnosis==
Shown below is an algorithm summarizing the diagnosis of <nowiki>[[disease name]]</nowiki> according the the [...] guidelines.
{{familytree/start |summary=PE diagnosis Algorithm.}}
{{familytree | | | | A01 | | | A01= }}
{{familytree | | | | |!| | | | }}
{{familytree | | | | B01 | | | B01= }}
{{familytree | | |,|-|^|-|.| | }}
{{familytree | | C01 | | C02 | C01= | C02= }}
{{familytree/end}}


==Treatment==
==Treatment==
Line 97: Line 88:
[[Pyrimethamine]], [[Sulfadiazine]], and [[folinic acid]].<ref name="pmid23343802">{{cite journal |vauthors=Paquet C, Yudin MH |title=Toxoplasmosis in pregnancy: prevention, screening, and treatment |journal=J Obstet Gynaecol Can |volume=35 |issue=1 |pages=78–81 |date=January 2013 |pmid=23343802 |doi=10.1016/s1701-2163(15)31053-7 |url= |issn=}}</ref>||
[[Pyrimethamine]], [[Sulfadiazine]], and [[folinic acid]].<ref name="pmid23343802">{{cite journal |vauthors=Paquet C, Yudin MH |title=Toxoplasmosis in pregnancy: prevention, screening, and treatment |journal=J Obstet Gynaecol Can |volume=35 |issue=1 |pages=78–81 |date=January 2013 |pmid=23343802 |doi=10.1016/s1701-2163(15)31053-7 |url= |issn=}}</ref>||
||
||
|❑ Pregnant mother should avoid eating raw, undercooked, and cured meats.<ref name="pmid16126501">{{cite journal |vauthors=Kravetz JD, Federman DG |title=Prevention of toxoplasmosis in pregnancy: knowledge of risk factors |journal=Infect Dis Obstet Gynecol |volume=13 |issue=3 |pages=161–5 |date=September 2005 |pmid=16126501 |pmc=1784564 |doi=10.1080/10647440500068305 |url= |issn=}}</ref>
|❑ [[Pregnant]] mother should avoid eating raw, undercooked, and cured meats.<ref name="pmid16126501">{{cite journal |vauthors=Kravetz JD, Federman DG |title=Prevention of toxoplasmosis in pregnancy: knowledge of risk factors |journal=Infect Dis Obstet Gynecol |volume=13 |issue=3 |pages=161–5 |date=September 2005 |pmid=16126501 |pmc=1784564 |doi=10.1080/10647440500068305 |url= |issn=}}</ref>
 


❑ Pregnant mother should avoid contact with cat litter.<ref name="pmid16126501">{{cite journal |vauthors=Kravetz JD, Federman DG |title=Prevention of toxoplasmosis in pregnancy: knowledge of risk factors |journal=Infect Dis Obstet Gynecol |volume=13 |issue=3 |pages=161–5 |date=September 2005 |pmid=16126501 |pmc=1784564 |doi=10.1080/10647440500068305 |url= |issn=}}</ref>
❑ Pregnant mother should avoid contact with cat litter.<ref name="pmid16126501">{{cite journal |vauthors=Kravetz JD, Federman DG |title=Prevention of toxoplasmosis in pregnancy: knowledge of risk factors |journal=Infect Dis Obstet Gynecol |volume=13 |issue=3 |pages=161–5 |date=September 2005 |pmid=16126501 |pmc=1784564 |doi=10.1080/10647440500068305 |url= |issn=}}</ref>


❑ Wash hands more frequently, especially after touching soil gardening.<ref name="pmid16126501">{{cite journal |vauthors=Kravetz JD, Federman DG |title=Prevention of toxoplasmosis in pregnancy: knowledge of risk factors |journal=Infect Dis Obstet Gynecol |volume=13 |issue=3 |pages=161–5 |date=September 2005 |pmid=16126501 |pmc=1784564 |doi=10.1080/10647440500068305 |url= |issn=}}</ref>
❑ Wash hands more frequently, especially after touching soil gardening.<ref name="pmid16126501">{{cite journal |vauthors=Kravetz JD, Federman DG |title=Prevention of toxoplasmosis in pregnancy: knowledge of risk factors |journal=Infect Dis Obstet Gynecol |volume=13 |issue=3 |pages=161–5 |date=September 2005 |pmid=16126501 |pmc=1784564 |doi=10.1080/10647440500068305 |url= |issn=}}</ref>
Line 105: Line 98:
|
|
|-
|-
|[[Rubella]]||❑ Intrauterine rubella infection > 16 weeks:
|[[Rubella]]||❑ Intrauterine [[rubella]] infection > 16 weeks:
Reassurance  
Reassurance.       


❑ [[Congenital rubella syndrome]]: Supportive care and surveillance  
❑ [[Congenital rubella syndrome]]: Supportive care and surveillance.       


❑ Live, attenuated [[rubella]] [[vaccine]] is contraindicated during [[pregnancy]]  <ref name="pmid3288422">{{cite journal |vauthors=Freij BJ, South MA, Sever JL |title=Maternal rubella and the congenital rubella syndrome |journal=Clin Perinatol |volume=15 |issue=2 |pages=247–57 |date=June 1988 |pmid=3288422 |doi= |url= |issn=}}</ref>
❑ Live, attenuated [[rubella]] [[vaccine]] is contraindicated during [[pregnancy]]  <ref name="pmid3288422">{{cite journal |vauthors=Freij BJ, South MA, Sever JL |title=Maternal rubella and the congenital rubella syndrome |journal=Clin Perinatol |volume=15 |issue=2 |pages=247–57 |date=June 1988 |pmid=3288422 |doi= |url= |issn=}}</ref>
||
||
||❑ Immunization of seronegative women before pregnancy.
||❑ [[Immunization]] of seronegative women before [[pregnancy]].
 
 
❑ Nationally notifiable condition: Suspected [[congenital rubella syndrome]] must be reported to the local or state health department.<ref>[Centers for Disease Control and Prevention. Three Cases of Congenital Rubella Syndrome in the Post elimination Era: Maryland, Alabama, and Illinois, 2012. MMWR Morb Mortal Wkly Rep. 2013; 62(12): pp. 226–229. url: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6212a3.htm. ], additional text.</ref>
❑ Nationally notifiable condition: Suspected [[congenital rubella syndrome]] must be reported to the local or state health department.<ref>[Centers for Disease Control and Prevention. Three Cases of Congenital Rubella Syndrome in the Post elimination Era: Maryland, Alabama, and Illinois, 2012. MMWR Morb Mortal Wkly Rep. 2013; 62(12): pp. 226–229. url: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6212a3.htm. ], additional text.</ref>
|-
|-
|[[Cytomegalovirus]]<ref name="pmid29560263">{{cite journal |vauthors=Pass RF, Arav-Boger R |title=Maternal and fetal cytomegalovirus infection: diagnosis, management, and prevention |journal=F1000Res |volume=7 |issue= |pages=255 |date=2018 |pmid=29560263 |pmc=5832908 |doi=10.12688/f1000research.12517.1 |url= |issn=}}</ref>||❑ '''Fetus:'''  
|[[Cytomegalovirus]]<ref name="pmid29560263">{{cite journal |vauthors=Pass RF, Arav-Boger R |title=Maternal and fetal cytomegalovirus infection: diagnosis, management, and prevention |journal=F1000Res |volume=7 |issue= |pages=255 |date=2018 |pmid=29560263 |pmc=5832908 |doi=10.12688/f1000research.12517.1 |url= |issn=}}</ref>||❑ '''Fetus:'''  
*Severe [[anemia]]: Intrauterine blood transfusions
*Severe [[anemia]]: Intrauterine [[Blood transfusion|blood transfusions]]
*[[Thrombocytopenia]]: Platelet transfusions
*[[Thrombocytopenia]]: [[Platelet transfusions]]


❑ '''Newborn:'''  
❑ '''Newborn:'''  


*Supportive therapy of symptoms,[[Ganciclovir]]<ref name="pmid12915819">{{cite journal |vauthors=Kimberlin DW, Lin CY, Sánchez PJ, Demmler GJ, Dankner W, Shelton M, Jacobs RF, Vaudry W, Pass RF, Kiell JM, Soong SJ, Whitley RJ |title=Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial |journal=J Pediatr |volume=143 |issue=1 |pages=16–25 |date=July 2003 |pmid=12915819 |doi=10.1016/s0022-3476(03)00192-6 |url= |issn=}}</ref>, [[valganciclovir]], or [[foscarnet]]
*Supportive therapy of symptoms,[[Ganciclovir]]<ref name="pmid12915819">{{cite journal |vauthors=Kimberlin DW, Lin CY, Sánchez PJ, Demmler GJ, Dankner W, Shelton M, Jacobs RF, Vaudry W, Pass RF, Kiell JM, Soong SJ, Whitley RJ |title=Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial |journal=J Pediatr |volume=143 |issue=1 |pages=16–25 |date=July 2003 |pmid=12915819 |doi=10.1016/s0022-3476(03)00192-6 |url= |issn=}}</ref>, [[Valganciclovir]], or [[Foscarnet]]


❑ '''Mother:'''  
❑ '''Mother:'''  


*[[valacyclovir]].
*[[Valacyclovir]].
||
||
||❑ Frequent hand washing.
||❑ Frequent hand washing.
❑ Pregnant women with risk factors for [[TORCH]] infection should avoid potentially contaminated workplaces such as schools, paediatric clinics <ref>[Julie Johnson, MD, Brenna Anderson, MD, MSc, and Robert F. Pass, MD. Prevention of Maternal and Congenital Cytomegalovirus Infection. Clinical Obstetrics and Gynecology. 2013. url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3347968/], additional text.</ref>
 
 
[[Pregnant]] women with risk factors for [[TORCH]] infection should avoid potentially contaminated workplaces such as schools, paediatric clinics. <ref>[Julie Johnson, MD, Brenna Anderson, MD, MSc, and Robert F. Pass, MD. Prevention of Maternal and Congenital Cytomegalovirus Infection. Clinical Obstetrics and Gynecology. 2013. url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3347968/], additional text.</ref>
|-
|-
|[[Herpesviru]]s||❑ [[Acyclovir]] & Supportive care
|[[Herpesvirus]]<ref name="pmid22566740">{{cite journal |vauthors=Straface G, Selmin A, Zanardo V, De Santis M, Ercoli A, Scambia G |title=Herpes simplex virus infection in pregnancy |journal=Infect Dis Obstet Gynecol |volume=2012 |issue= |pages=385697 |date=2012 |pmid=22566740 |pmc=3332182 |doi=10.1155/2012/385697 |url= |issn=}}</ref>||❑ [[Acyclovir]] 400 mg tablets 3 times daily
||Only for [[herpes simplex]] <ref>[ Riley LE, Wald A. Genital herpes simplex virus infection and pregnancy. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. http://www.uptodate.com/contents/genital-herpes-simplex-virus-infection-and-pregnancy. Last updated June 18, 2016. Accessed March 22, 2017.], additional text.</ref>
OR
||❑ Antiviral therapy ([[acyclovir]]) beginning at 36 weeks of gestation for individuals with a known history of [[HSV]] lesions.
 
❑ Cesarean section in women with active genital lesions or prodromal symptoms such as burning pain.<ref>[ Demmler-Harrison GJ. Neonatal herpes simplex virus infection: Management and prevention. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. http://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention. Last updated February 16, 2016. Accessed March 22, 2017. ], additional text.</ref>
❑ [[Acyclovir]] 200 mg tablets 4 times a day from week 36 until [[delivery]], and viral cultures on cervical-vaginal secretions from 36th week of [[gestation]] are required.
 
 
[[Valacyclovir]] at a dose of 200 mg 2 times a day.<ref name="pmid22566740">{{cite journal |vauthors=Straface G, Selmin A, Zanardo V, De Santis M, Ercoli A, Scambia G |title=Herpes simplex virus infection in pregnancy |journal=Infect Dis Obstet Gynecol |volume=2012 |issue= |pages=385697 |date=2012 |pmid=22566740 |pmc=3332182 |doi=10.1155/2012/385697 |url= |issn=}}</ref>
||
||❑ [[Antiviral]] therapy ([[Acyclovir]]) beginning at 36 weeks of [[gestation]] for individuals with a known history of [[HSV]] lesions.
 
 
[[Caesarean section|Cesarean]] section in women with active genital lesions or prodromal symptoms such as burning [[pain]].
|-
|-
|[[Parvovirus]]||❑ Intrauterine fetal blood transfusion in cases of severe fetal anemia
|[[Parvovirus]]<ref name="pmid22439064">{{cite journal |vauthors=Giorgio E, De Oronzo MA, Iozza I, Di Natale A, Cianci S, Garofalo G, Giacobbe AM, Politi S |title=Parvovirus B19 during pregnancy: a review |journal=J Prenat Med |volume=4 |issue=4 |pages=63–6 |date=October 2010 |pmid=22439064 |pmc=3279187 |doi= |url= |issn=}}</ref>||❑ Intrauterine [[fetal]] [[blood transfusion]] in cases of severe fetal [[anemia]].
||
||
||❑ Hand hygiene (frequent hand washing)
||❑ Hand hygiene (frequent hand washing).
❑ Pregnant women with risk factors for [[TORCH]] infection should avoid potentially contaminated workplaces such as schools, paediatric clinics.<ref>[Lamont RF, Sobel JD, Vaisbuch E, et al. Parvovirus B19 infection in human pregnancy. BJOG. 2010; 118(2): pp. 175–186. doi: 10.1111/j.1471-0528.2010.02749.x  ], additional text.</ref>
 
 
❑ Pregnant women with risk factors for [[TORCH]] infection should avoid potentially contaminated workplaces such as schools, paediatric clinics.
|-
|-
|Acquired immunodeficiency syndrome ([[AIDS]])||❑ M'''other: T'''he US Public Health Service<ref>[Centers for Disease Control and Prevention: Recommendations of the US Public Health Service Task Force on use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 43:1, 1994 ], additional text.</ref> published recommendations for the use of ZDV or AZT to reduce the risk of [[HIV]] transmission from infected women to their infants as a result of the AIDS Clinical Trials Group (ACTG) which includes:
|[[Acquired immunodeficiency syndrome]] ([[AIDS]])||❑ '''Mother''':
The US Public Health Service<ref name="urlRecommendations of the U.S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immunodeficiency Virus">{{cite web |url=https://www.cdc.gov/mmwr/preview/mmwrhtml/00032271.htm#00000604.htm |title=Recommendations of the U.S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immunodeficiency Virus |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref>published recommendations for the use of ZDV or AZT to reduce the risk of [[HIV]] transmission from infected women to their infants as a result of the AIDS Clinical Trials Group (ACTG) which includes:


*'''Antepartum:''' ZDV, 100 mg orally five times per day, starting at 14–34 weeks.
*'''Antepartum:''' ZDV, 100 mg orally five times per day, starting at 14–34 weeks.<ref name="urlRecommendations of the U.S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immunodeficiency Virus">{{cite web |url=https://www.cdc.gov/mmwr/preview/mmwrhtml/00032271.htm#00000604.htm |title=Recommendations of the U.S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immunodeficiency Virus |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref>
*'''Intrapartum:''' ZDV, 2 mg/kg intravenously (IV), loading dose, given over 1 hour, followed by 1 mg/kg/hr IV until delivery.
*'''Intrapartum:''' ZDV, 2 mg/kg intravenously (IV), loading dose, given over 1 hour, followed by 1 mg/kg/hr IV until delivery.<ref name="urlRecommendations of the U.S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immunodeficiency Virus">{{cite web |url=https://www.cdc.gov/mmwr/preview/mmwrhtml/00032271.htm#00000604.htm |title=Recommendations of the U.S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immunodeficiency Virus |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref>
*
*
*


❑ '''Newborn:''' ZDV syrup 2 mg/kg orally every 6 hours, beginning 8–12 hours after birth for the first 6 weeks of life
❑ '''Newborn:'''  
||❑ A scheduled cesarean section can reduce vertical transmission  to 2%. It is not yet known if there is a significant benefit from cesarean delivery in patients who have viral loads of less than 1000 copies/ml who are on HAART. Maternal morbidity is greater with cesarean delivery, particularly in those women with low CD4 cell counts. Therefore, women who are [[HIV]] positive must be counseled about the maternal risks and potential benefits of both ZDV prophylaxis and cesarean delivery so that they can make informed choices. If cesarean delivery is chosen, it should be performed electively at 38 weeks of gestation. ZDV should begin 3 hours prior to delivery. It is important to use perioperative prophylactic antibiotics to reduce maternal infectious morbidity. The management of labor (if the patient chooses this option) should include avoidance of scalp electrodes and scalp sampling.<ref>[ The International Perinatal HIV Group: The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N Engl J Med 340: 977, 1999 ], additional text.</ref> ,<ref>[ACOG Committee Opinion no. 234, May 2000 ], additional text.</ref>
 
||The newborn should be carefully cleaned of maternal blood and secretions. There is no evidence that the postpartum course is altered. The virus has been isolated from breast milk, and although the risk of transfer is not known, breastfeeding is not recommended when there is a suitable alternative, as exists in the developed world. A final step in the case of the HIV-infected patient is to see that the patient receives ongoing care. Even if she is asymptomatic after delivery, she will require support and surveillance for disease progression.<ref>[ Ziegler JB, Cooper DA, Johnson RO: Postnatal transmission of AIDS-associated retrovirus from mother to infant. Lancet 1: 896, 1985 ], additional text.</ref> ,<ref>[Centers for Disease Control: Recommendations for assisting in the prevention of perinatal transmission of human T lymphocyte virus type lymphadenopathy- associated virus and acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 34: 721, 1985 ], additional text.</ref>
ZDV syrup 2 mg/kg orally every 6 hours, beginning 8–12 hours after birth for the first 6 weeks of life
||❑ A scheduled [[Caesarean section|cesarean section]] can reduce vertical transmission  to 2%. It is unclear if there is a significant benefit from cesarean delivery in patients who have viral loads of less than 1000 copies/ml who are on HAART.<ref name="pmid17825656">{{cite journal |vauthors=Jamieson DJ, Read JS, Kourtis AP, Durant TM, Lampe MA, Dominguez KL |title=Cesarean delivery for HIV-infected women: recommendations and controversies |journal=Am J Obstet Gynecol |volume=197 |issue=3 Suppl |pages=S96–100 |date=September 2007 |pmid=17825656 |doi=10.1016/j.ajog.2007.02.034 |url= |issn=}}</ref>❑ [[Maternal]] morbidity is greater with [[cesarean delivery]], particularly in those women with low CD4 cell counts. Therefore, women who are [[HIV]] positive must be counseled about the maternal risks and potential benefits of both ZDV prophylaxis and [[cesarean delivery]] so that they can make informed choices.  
 
 
If [[cesarean delivery]] is chosen, it should be performed electively at 38 weeks of gestation. ZDV should begin 3 hours prior to delivery. It is important to use perioperative prophylactic antibiotics to reduce maternal infectious morbidity.
 
 
The management of labor should include avoidance of scalp electrodes and scalp sampling.
||The newborn should be carefully cleaned off maternal blood and secretions.  
 
 
❑ [[Breastfeeding]] is not recommended when there is a suitable alternative.
 
Even if she is asymptomatic after delivery, she will require support and surveillance for disease progression.<ref name="pmid10099139">{{cite journal |vauthors=Andiman W, Bryson Y, de Martino M, Fowler M, Harris D, Hutto C, Korber B, Kovacs A, Landesman S, Lindsay M, Lapointe N, Mandelbrot L, Newell M-L, Peavy H, Read J, Rudin C, Semprini A, Simonds R, Tuomala R |title=The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1--a meta-analysis of 15 prospective cohort studies |journal=N Engl J Med |volume=340 |issue=13 |pages=977–87 |date=April 1999 |pmid=10099139 |doi=10.1056/NEJM199904013401301 |url= |issn=}}</ref>
|-
|-
|[[Varicella zoster virus]]||'''pregnant women or newborns with (severe) infection:''' [[acyclovir]]  
|[[Varicella zoster virus]]||'''Pregnant women or newborns with (severe) infection:''' [[Acyclovir]] <ref name="pmid29565203">{{cite journal |vauthors=Hayward K, Cline A, Stephens A, Street L |title=Management of herpes zoster (shingles) during pregnancy |journal=J Obstet Gynaecol |volume=38 |issue=7 |pages=887–894 |date=October 2018 |pmid=29565203 |doi=10.1080/01443615.2018.1446419 |url= |issn=}}</ref>
Administer postexposure prophylaxis in newborns if mother displays symptoms of varicella < 5 days before delivery: IgG antibodies (varicella-zoster immune globulin, VZIG)
Administer postexposure prophylaxis in newborns if mother displays symptoms of varicella up to 7 days before delivery or up to 28 days after delivery: IgG antibodies (varicella-zoster immune globulin, VZIG)<ref name="pmid11297117">{{cite journal |vauthors=Heuchan AM, Isaacs D |title=The management of varicella-zoster virus exposure and infection in pregnancy and the newborn period. Australasian Subgroup in Paediatric Infectious Diseases of the Australasian Society for Infectious Diseases |journal=Med J Aust |volume=174 |issue=6 |pages=288–92 |date=March 2001 |pmid=11297117 |doi= |url= |issn=}}</ref>
||
||
||Immunization of seronegative women before pregnancy
||Immunization of seronegative women of child breeding age before pregnancy.<ref name="pmid18275568">{{cite journal |vauthors=Daley AJ, Thorpe S, Garland SM |title=Varicella and the pregnant woman: prevention and management |journal=Aust N Z J Obstet Gynaecol |volume=48 |issue=1 |pages=26–33 |date=February 2008 |pmid=18275568 |doi=10.1111/j.1479-828X.2007.00797.x |url= |issn=}}</ref>


VZIG in pregnant women without immunity within 10 days of exposure.<ref>[ Centers for Disease Control and Prevention. 2017 Nationally Notifiable Conditions. https://wwwn.cdc.gov/nndss/conditions/notifiable/2017/. Updated January 1, 2017. Accessed March 22, 2017], additional text.</ref>
VZIG in pregnant women without immunity within 10 days of exposure.<ref>[ Centers for Disease Control and Prevention. 2017 Nationally Notifiable Conditions. https://wwwn.cdc.gov/nndss/conditions/notifiable/2017/. Updated January 1, 2017. Accessed March 22, 2017], additional text.</ref>
Line 159: Line 181:
|[[Hepatitis]]||
|[[Hepatitis]]||
||
||
||'''[[Hepatitis A]]:'''pregnant or not, who is exposed by contact or travel in endemic areas should receive immune serum globulin (0.02–0.05 mL/kg). If exposure is prolonged and close, the higher dose should be used and repeated every 4–6 months. <ref>[ Amstey MS: Treatment and prevention of viral infections. Clin Obstet Gynecol 31: 501, 1988 ], additional text.</ref> '''[[Hepatitis B]]:''' infants born to mothers with circulating HBV. These infants, if chronically infected, are at high long-term risk for hepatic cancer. Because of this and because it is possible to prevent perinatal transmission, particularly if infection occurs in late pregnancy, testing for HBV surface antigen is recommended as a part of routine prenatal testing. <ref>[ American College of Obstetricians and Gynecologists: Guidelines for Hepatitis B Virus Screening and Vaccination During Pregnancy. ACOG Committee Opinion 78. Washington DC, ACOG, 1990 ], additional text.</ref>. Infants born to HBV-positive mothers should receive 0.5 mL of hepatitis B immune globulin within 12 hours of birth and simultaneously receive the first dose of HBV vaccine (half the adult dose). The remaining doses should follow the adult schedule. There is no reason to modify the obstetric management because cesarean delivery will not modify the risk. The HBV vaccine now in use is a recombinant product, poses no infectious risk, and can be used in pregnancy for women at risk. Complete immunization requires the initial dose with repeated doses at 1 and 6 months. Healthcare workers should know their HBV immune status and, if susceptible, should be vaccinated. '''[[Hepatitis C]]:''' At present, no vaccine is available for [[HCV]], and there are insufficient data to recommend pregnancy termination. The management of the pregnant woman infected with HCV must be individualized until further evidence is available to make reasonable recommendations.<ref>[ Duff P. Hepatitis in pregnancy. Semin Perinatol 1998; 22: 277-83 ], additional text.</ref>
||'''[[Hepatitis A]]:'''
❑ Maintain hygienic practices such as hand washing with safe water, particularly before handling food, avoiding drinking water or using ice cubes of unknown purity, and avoiding eating unpeeled fruits and vegetables.
 
 
❑ The HAV vaccine is safe and develops protective levels of antibodies 2 weeks after the first dose of the vaccine  and persists at least 10 to 29 years, if not lifelong after receiving the second dose. So, it should be administered before travelling to endemic areas.<ref name="pmid26881283">{{cite journal |vauthors=Chaudhry SA, Koren G |title=Hepatitis A infection during pregnancy |journal=Can Fam Physician |volume=61 |issue=11 |pages=963–4 |date=November 2015 |pmid=26881283 |pmc=4642904 |doi= |url= |issn=}}</ref>
 
 
'''[[Hepatitis B]]:'''  
 
❑ Testing for HBV surface antigen is recommended as a part of routine prenatal testing.
 
 
Infants born to HBV-positive mothers should receive 0.5 mL of hepatitis B immune globulin within 12 hours of birth and simultaneously receive the first dose of HBV vaccine (half the adult dose). The remaining doses should follow the adult schedule. Complete immunization requires the initial dose with repeated doses at 1 and 6 months.  
 
 
'''[[Hepatitis C]]:'''  
 
At present, no vaccine is available for [[HCV]] .
|-
|-
|[[Influenza]]||Prompt empiric treatment with appropriate neuraminidase inhibitors ([[oseltamivir]] and [[zanamivir]]) appeared to decrease the risk of severe disease. <ref>[Mosby LG, Ellington SR, Forhan SE, Yeung LF, Perez M, Shah MM, MacFarlane K, Laird SK, House LD, Jamieson DJ. The Centers for Disease Control and Prevention's maternal health response to 2009 H1N1 influenza. Am J Obstet Gynecol. 2011 Jun;204(6 Suppl 1):S7-12. Epub 2011 Mar 31], additional text.</ref>
|[[Influenza]]||Prompt antiviral therapy should be given where the medications reduce the risk of complications in pregnant women and reduce the teratogenic effects of the influenza infection.<ref name="pmid26836818">{{cite journal |vauthors=Ghulmiyyah LM, Alame MM, Mirza FG, Zaraket H, Nassar AH |title=Influenza and its treatment during pregnancy: A review |journal=J Neonatal Perinatal Med |volume=8 |issue=4 |pages=297–306 |date=2015 |pmid=26836818 |doi=10.3233/NPM-15814124 |url= |issn=}}</ref>
||Preterm delivery and cesarean delivery were commonly associated with maternal illness with preterm birth rates as high as 30% and cesarean section rates of nearly double the current national baseline.<ref>[  Mosby LG, Ellington SR, Forhan SE, Yeung LF, Perez M, Shah MM, MacFarlane K, Laird SK, House LD, Jamieson DJ. The Centers for Disease Control and Prevention's maternal health response to 2009 H1N1 influenza. Am J Obstet Gynecol. 2011 Jun;204(6 Suppl 1):S7-12. Epub 2011 Mar 31. ], additional text.</ref>
❑ Trans placental transfer of oseltamivir to fetus may occur. But there is no evidence of adverse fetal outcomes as of now.<ref name="pmid26836818">{{cite journal |vauthors=Ghulmiyyah LM, Alame MM, Mirza FG, Zaraket H, Nassar AH |title=Influenza and its treatment during pregnancy: A review |journal=J Neonatal Perinatal Med |volume=8 |issue=4 |pages=297–306 |date=2015 |pmid=26836818 |doi=10.3233/NPM-15814124 |url= |issn=}}</ref>
||[[Influenza vaccination]] is now an important component of antenatal care. The CDC recommends that women who will be pregnant during the flu season (October through mid May) be vaccinated. <ref>[ Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization practices (ACIP) MMWR. Recomm Rep 2004; 53(RR-6): 1-40 ], additional text.</ref> Vaccination may be performed in all three trimesters. Specific vaccines prepared for epidemic strains are more effective than the poly antigenic preparations. Complications of vaccination are generally mild, except for [[Guillain-Barré syndrome]]. This is characterized by progressive ascending paralysis but fortunately is usually self-limited and reversible. Evidence from the swine flu epidemic of 1976 suggests that the incidence is approximately 1 in 100,000 vaccinations. The frequency of complications does not appear to be altered by pregnancy. The theoretical risks of vaccination are outweighed by its benefits.
||
||Vaccination is the most effective strategy for preventing influenza infection during pregnancy whereby can protect both mother and the fetus.
|-
|-
|Genital condylomata||The treatment of choice for large-volume and symptomatic disease is the carbon dioxide (CO2) laser, <ref>[Ferenczy A: Treating genital condyloma during pregnancy with the carbon dioxide laser. Am J Obstet Gynecol 148: 9, 1989], additional text.</ref> and it is suggested that treatment with it be carried out in the third trimester to reduce the chances of recurrence from latent HPV infection at the time of delivery. Interferons have been used successfully <ref>[ Friedman-Kien AE, Eron LJ, Conant M: Natural interferon alfa for treatment of [[condylomata acuminata]]. JAMA 259: 533, 1988], additional text.</ref> but are not yet approved for clinical use.[[Trichloroacetic acid]] is the best choice for isolated or small-volume genital disease.<ref>[Choo QL, Kuo G, Weiner, AJ et al: Isolation of a DNA clone derived from blood-borne non-A, non-B viral hepatitis genome. Science 244: 359, 1989 ], additional text.</ref>
|[[Group B streptococci]]<ref name="urlGroup B Streptococcus And Pregnancy - StatPearls - NCBI Bookshelf">{{cite web |url=https://www.ncbi.nlm.nih.gov/books/NBK482443/ |title=Group B Streptococcus And Pregnancy - StatPearls - NCBI Bookshelf |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref>||❑ Intravenous penicillin G is the treatment of choice for intrapartum antibiotic prophylaxis against Group B Streptococci.
||There is almost never a reason to perform a cesarean section for condylomata if the patient is seen sufficiently early in pregnancy to accomplish treatment.
 
||
 
|-
❑ Penicillin G 5 million units intravenous is administered as a loading dose, followed by 2.5 to 3 million units every 4 hours during labor until delivery.<ref name="pmid29370038">{{cite journal |vauthors= |title=Committee Opinion No. 485: Prevention of Early-Onset Group B Streptococcal Disease in Newborns: Correction |journal=Obstet Gynecol |volume=131 |issue=2 |pages=397 |date=February 2018 |pmid=29370038 |doi=10.1097/AOG.0000000000002466 |url= |issn=}}</ref><ref name="urlGroup B Streptococcus And Pregnancy - StatPearls - NCBI Bookshelf">{{cite web |url=https://www.ncbi.nlm.nih.gov/books/NBK482443/ |title=Group B Streptococcus And Pregnancy - StatPearls - NCBI Bookshelf |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref>
|[[Group B streptococci]]||As stated earlier, [[penicillin]] is the drug of choice for GBS treatment and prophylaxis. [[Ampicillin]] is an acceptable alternative. Penicillin is preferred due to its narrow spectrum of activity. Five million units of [[penicillin G]] is given as the loading dose. This is followed with 2.5–3.0 million units every 4 hours until delivery. The dose of [[ampicillin]] is 2 g loading followed by 1 g every 4 hours. Increased resistance of GBS isolates to second-line therapies has been noted. Susceptibility testing should be ordered in patients who are allergic to [[penicillin]]. [[Cefazolin]] is recommended for patients that are not at high risk for [[anaphylaxis]]. Two grams are given intravenously followed by 1 g every 8 hours. If the patient is a high risk of anaphylaxis, treatment would depend on the susceptibility of the isolate. [[Clindamycin]] (900 mg IV every 8 hours). [[Erythromycin]] is no longer an acceptable alternative for penicillin allergic women at high risk for anaphylaxis. Patients at high risk of [[anaphylaxis]] with unknown susceptibility or resistance to clindamycin, should be treated with vancomycin. The dose of vancomycin is 1 g every 12 hours until delivery. It must be emphasized that [[vancomycin]] is reserved for patients at high risk for [[anaphylaxis]].<ref>[Verani JR, McGee L, Schrag SJ; Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010 Nov 19;59(RR-10):1-36], additional text.</ref>
 
 
Ampicillin is a reasonable alternative to penicillin G, which is administered as a 2 gm intravenous loading dose followed by 1 gm intravenous every 4 hours during labor until delivery.
 
 
❑ Antibiotic prophylaxis in patients with a history of anaphylaxis, angioedema, respiratory distress, or urticaria following penicillin or cephalosporin is guided by antibiotic susceptibility testing. If GBS is sensitive to both clindamycin and erythromycin, then clindamycin 900 mg intravenous every 8 hours is recommended for GBS prophylaxis during labor until delivery.<ref name="urlGroup B Streptococcus And Pregnancy - StatPearls - NCBI Bookshelf">{{cite web |url=https://www.ncbi.nlm.nih.gov/books/NBK482443/ |title=Group B Streptococcus And Pregnancy - StatPearls - NCBI Bookshelf |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref><ref name="pmid29370038">{{cite journal |vauthors= |title=Committee Opinion No. 485: Prevention of Early-Onset Group B Streptococcal Disease in Newborns: Correction |journal=Obstet Gynecol |volume=131 |issue=2 |pages=397 |date=February 2018 |pmid=29370038 |doi=10.1097/AOG.0000000000002466 |url= |issn=}}</ref>
 
 
❑ If the culture returns resistant to erythromycin, vancomycin 1 gm intravenously every 12 hours is recommended for GBS prophylaxis.
 
 
If patient is penicillin allergic, vancomycin is the choice of treatment.
 
 
❑Cefazolin 2 gram intravenous loading dose followed by 1 gm every 8 hours may be used in patients without a history of anaphylaxis, angioedema, respiratory distress, or urticaria following penicillin or cephalosporin administration.<ref name="urlGroup B Streptococcus And Pregnancy - StatPearls - NCBI Bookshelf">{{cite web |url=https://www.ncbi.nlm.nih.gov/books/NBK482443/ |title=Group B Streptococcus And Pregnancy - StatPearls - NCBI Bookshelf |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref>
<br />
||
||
||Women with intact membranes who present with threatened [[preterm delivery]] and unknown GBS status should receive IAP until GBS culture results are available. If GBS is negative, or the patient is not in true labor, IAP may be discontinued and re-screening should be done at 35–37 weeks.<ref>[  Verani JR, McGee L, Schrag SJ; Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010 Nov 19;59(RR-10):1-36.  ], additional text.</ref>
||Initiating antibiotic prophylaxis greater than 4 hours before delivery is considered to be adequate antibiotic prophylaxis and is effective in the prevention of transmission of GBS to the fetus.<ref name="urlGroup B Streptococcus And Pregnancy - StatPearls - NCBI Bookshelf">{{cite web |url=https://www.ncbi.nlm.nih.gov/books/NBK482443/ |title=Group B Streptococcus And Pregnancy - StatPearls - NCBI Bookshelf |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref>
|-
|-
|[[Listeriosis]]||IV [[ampicillin]] and [[gentamicin]] (for both mother and newborn)
|[[Listeriosis]]||IV [[ampicillin]] and [[gentamicin]] (for both mother and newborn)
Line 179: Line 234:
*Avoidance of potentially contaminated water and food: See “Food and water safety” in food poisoning.
*Avoidance of potentially contaminated water and food: See “Food and water safety” in food poisoning.
*Nationally notifiable condition: [[Listeriosis]] must be reported to the local or state health department.<ref>[ Janakiraman V. Listeriosis in pregnancy: diagnosis, treatment, and prevention. Rev Obstet Gynecol. 2008; 1(4): pp. 179–85. pmid: 19173022. ], additional text.</ref>
*Nationally notifiable condition: [[Listeriosis]] must be reported to the local or state health department.<ref>[ Janakiraman V. Listeriosis in pregnancy: diagnosis, treatment, and prevention. Rev Obstet Gynecol. 2008; 1(4): pp. 179–85. pmid: 19173022. ], additional text.</ref>
|-
|[[Tuberculosis]]||* recent converters should be treated with [[isoniazid]], 300 mg/day, starting after the [[first trimester]] and continuing for 6–9 months. Women younger than 35 years of age with a positive [[PPD]] of unknown duration should receive isoniazid, 300 mg/day, for 6 months after delivery.
*Patients with active disease should be started on treatment immediately on diagnosis, with dual-agent therapy for 9 months. [[Isoniazid]] 300 mg/day, combined with [[rifampin]], 600 mg/day, is the standard. [[Ethambutol]], 2.5 g/day, may be substituted in case of resistance. [[Pyridoxine]] (vitamin B6) supplementation, 50 mg/day, is essential for all patients receiving isoniazid. None of these medications are known to have adverse effects in pregnancy. Breastfeeding is considered safe during maternal treatment as long as the infant is not receiving antituberculous therapy. Infants born to women with active tuberculosis should receive [[isoniazid]] prophylaxis (10 mg/kg/day) until maternal disease has been inactive for 3 months. <ref>[ Ricci JM, Fojaco RM, Fojaco RM, O'sullivan MJ: Congenital syphillis: The University of Miami/Jackson Memorial Medical Center Experience, 1986-1988. Obstet Gynecol 74: 687, 1989 ], additional text.</ref>
||
||Prophylaxis is not recommended for women older than 35 years of age in the absence of active disease because of concern about [[hepatotoxicity]].
|-
|-
|[[Syphilis]]||Therapy is indicated in the gravida with a positive [[FTA-ABS]] of recent onset, and the drug of choice is [[penicillin]]. <ref>[ Centers for Disease Control: Syphilis: CDC recommended treatment schedules. J Infect Dis 134: 97, 1976], additional text.</ref> The regimen recommended is the same as in the nonpregnant woman. For early syphilis, a single dose of 2.4 million units of [[benzathine penicillin G]] is recommended. Some recommend a follow-up dose 1 week later, particularly in the [[third trimester]]. For late-stage syphilis (more than 1 year of duration), three doses are recommended. For the patient allergic to penicillin, treatment with [[penicillin]] after oral [[desensitization]] is recommended. This should be done in a facility that has appropriate provisions for resuscitation, if needed. <ref>[ ACOG Educational Bulletin No 245, March 1998, American College of Obstetricians and Gynecologists ], additional text.</ref>||
|[[Syphilis]]||Therapy is indicated in the gravida with a positive [[FTA-ABS]] of recent onset, and the drug of choice is [[penicillin]]. <ref>[ Centers for Disease Control: Syphilis: CDC recommended treatment schedules. J Infect Dis 134: 97, 1976], additional text.</ref> The regimen recommended is the same as in the nonpregnant woman. For early syphilis, a single dose of 2.4 million units of [[benzathine penicillin G]] is recommended. Some recommend a follow-up dose 1 week later, particularly in the [[third trimester]]. For late-stage syphilis (more than 1 year of duration), three doses are recommended. For the patient allergic to penicillin, treatment with [[penicillin]] after oral [[desensitization]] is recommended. This should be done in a facility that has appropriate provisions for resuscitation, if needed. <ref>[ ACOG Educational Bulletin No 245, March 1998, American College of Obstetricians and Gynecologists ], additional text.</ref>||
Line 200: Line 249:
||
||
  ||Prevention of perinatal infection is best accomplished by careful maternal screening and treatment.
  ||Prevention of perinatal infection is best accomplished by careful maternal screening and treatment.
|-
|Mycoplasmas||The treatment for the pregnant woman and the neonate is [[clindamycin]] for Mycoplasma hominis and erythromycin for [[M. pneumoniae]] and Ureaplasma urealyticum.
||
||These associations have not been conclusively established, and, consequently, treatment should be used only if there is reasonable evidence for causality in a given situation.
|-
|-
|Chlamydia||❑ Recommended treatment :
|Chlamydia||❑ Recommended treatment :

Latest revision as of 08:45, 22 May 2021


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rinky Agnes Botleroo, M.B.B.S.

Synonyms and keywords: Neonatal infection; TORCH infection

Perinatal infection Resident Survival Guide Microchapters
Overview
Causes
Diagnosis
Treatment
Dos
Don'ts


Overview

Most of the perinatal infections in the neonate are bacterial. These infections may be acquired from the mother prior to or at birth or from environmental sources. Premature babies are prone to perinatal infections. Neonates, especially those born prematurely have very limited ability to express symptoms, so, even minor deviations from normal behaviour should suggest bacterial disease. Chronic congenital and perinatal infections are usually asymptomatic in mother and neonate and may remain latent or sub-clinically active in host tissue for prolonged time.It may cause insidious injury to the central nervous and perceptual systems. When noticeable, these infections almost invariably cause mental or perceptual handicaps or both. Cytomegalovirus is the most common cause of congenital infections and the fetal effects of primary maternal infection during gestation can be devastating.Perinatal infection occurring in the 1st few days to 14 days occurs due to contact with the pathogens present in the cervico-vaginal canal during delivery. causes are Escherichia coli, Group B beta haemolytic Streptococci,Gonococci, Listeria monocytogenes ,Bacteroides species, Candida albicans, Cytomegalo virus,Herpes Simplex Virus Type-2.The mortality and morbidity associated with either acute or chronic infections is quite high. So, appropriate diagnosis and treatment is required and should be aggressive.

Causes

Perinatal infection occurring in the 1st few days to 14 days occurs due to contact with the pathogens present in the cervico-vaginal canal during delivery. causes are

Perinatal infections that occurs late, usually 3 to 6 weeks after birth are caused by environmental pathogens. Causes are

Several vertically transmitted infections are included in the TORCH complex:[1]

  1. T – toxoplasmosis from Toxoplasma gondii
  2. O – other infections (see below)
  3. R – rubella
  4. C – cytomegalovirus
  5. H – herpes simplex virus-2 or neonatal herpes simplex

Other infections include:

Diagnosis

Treatment

Disease Medical Therapy Surgery Prevention
Toxoplasmosis Mother:

Immediate administration of Spiramycin [2]

Fetus and Newborn:

Pyrimethamine, Sulfadiazine, and folinic acid.[2]||

Pregnant mother should avoid eating raw, undercooked, and cured meats.[3]


❑ Pregnant mother should avoid contact with cat litter.[3]


❑ Wash hands more frequently, especially after touching soil gardening.[3]

Rubella ❑ Intrauterine rubella infection > 16 weeks:

Reassurance.

Congenital rubella syndrome: Supportive care and surveillance.

❑ Live, attenuated rubella vaccine is contraindicated during pregnancy [4]

Immunization of seronegative women before pregnancy.


❑ Nationally notifiable condition: Suspected congenital rubella syndrome must be reported to the local or state health department.[5]

Cytomegalovirus[6] Fetus:

Newborn:

Mother:

❑ Frequent hand washing.


Pregnant women with risk factors for TORCH infection should avoid potentially contaminated workplaces such as schools, paediatric clinics. [8]

Herpesvirus[9] Acyclovir 400 mg tablets 3 times daily

OR

Acyclovir 200 mg tablets 4 times a day from week 36 until delivery, and viral cultures on cervical-vaginal secretions from 36th week of gestation are required.


Valacyclovir at a dose of 200 mg 2 times a day.[9]

Antiviral therapy (Acyclovir) beginning at 36 weeks of gestation for individuals with a known history of HSV lesions.


Cesarean section in women with active genital lesions or prodromal symptoms such as burning pain.

Parvovirus[10] ❑ Intrauterine fetal blood transfusion in cases of severe fetal anemia. ❑ Hand hygiene (frequent hand washing).


❑ Pregnant women with risk factors for TORCH infection should avoid potentially contaminated workplaces such as schools, paediatric clinics.

Acquired immunodeficiency syndrome (AIDS) Mother:

The US Public Health Service[11]published recommendations for the use of ZDV or AZT to reduce the risk of HIV transmission from infected women to their infants as a result of the AIDS Clinical Trials Group (ACTG) which includes:

  • Antepartum: ZDV, 100 mg orally five times per day, starting at 14–34 weeks.[11]
  • Intrapartum: ZDV, 2 mg/kg intravenously (IV), loading dose, given over 1 hour, followed by 1 mg/kg/hr IV until delivery.[11]

Newborn:

ZDV syrup 2 mg/kg orally every 6 hours, beginning 8–12 hours after birth for the first 6 weeks of life

❑ A scheduled cesarean section can reduce vertical transmission to 2%. It is unclear if there is a significant benefit from cesarean delivery in patients who have viral loads of less than 1000 copies/ml who are on HAART.[12]Maternal morbidity is greater with cesarean delivery, particularly in those women with low CD4 cell counts. Therefore, women who are HIV positive must be counseled about the maternal risks and potential benefits of both ZDV prophylaxis and cesarean delivery so that they can make informed choices.


❑ If cesarean delivery is chosen, it should be performed electively at 38 weeks of gestation. ZDV should begin 3 hours prior to delivery. It is important to use perioperative prophylactic antibiotics to reduce maternal infectious morbidity.


❑ The management of labor should include avoidance of scalp electrodes and scalp sampling.

❑ The newborn should be carefully cleaned off maternal blood and secretions.


Breastfeeding is not recommended when there is a suitable alternative.

❑ Even if she is asymptomatic after delivery, she will require support and surveillance for disease progression.[13]

Varicella zoster virus Pregnant women or newborns with (severe) infection: Acyclovir [14]

Administer postexposure prophylaxis in newborns if mother displays symptoms of varicella up to 7 days before delivery or up to 28 days after delivery: IgG antibodies (varicella-zoster immune globulin, VZIG)[15]

Immunization of seronegative women of child breeding age before pregnancy.[16]

VZIG in pregnant women without immunity within 10 days of exposure.[17]

Hepatitis Hepatitis A:

❑ Maintain hygienic practices such as hand washing with safe water, particularly before handling food, avoiding drinking water or using ice cubes of unknown purity, and avoiding eating unpeeled fruits and vegetables.


❑ The HAV vaccine is safe and develops protective levels of antibodies 2 weeks after the first dose of the vaccine and persists at least 10 to 29 years, if not lifelong after receiving the second dose. So, it should be administered before travelling to endemic areas.[18]


Hepatitis B:

❑ Testing for HBV surface antigen is recommended as a part of routine prenatal testing.


❑ Infants born to HBV-positive mothers should receive 0.5 mL of hepatitis B immune globulin within 12 hours of birth and simultaneously receive the first dose of HBV vaccine (half the adult dose). The remaining doses should follow the adult schedule. Complete immunization requires the initial dose with repeated doses at 1 and 6 months.


Hepatitis C:

❑ At present, no vaccine is available for HCV .

Influenza ❑ Prompt antiviral therapy should be given where the medications reduce the risk of complications in pregnant women and reduce the teratogenic effects of the influenza infection.[19]

❑ Trans placental transfer of oseltamivir to fetus may occur. But there is no evidence of adverse fetal outcomes as of now.[19]

Vaccination is the most effective strategy for preventing influenza infection during pregnancy whereby can protect both mother and the fetus.
Group B streptococci[20] ❑ Intravenous penicillin G is the treatment of choice for intrapartum antibiotic prophylaxis against Group B Streptococci.


❑ Penicillin G 5 million units intravenous is administered as a loading dose, followed by 2.5 to 3 million units every 4 hours during labor until delivery.[21][20]


❑ Ampicillin is a reasonable alternative to penicillin G, which is administered as a 2 gm intravenous loading dose followed by 1 gm intravenous every 4 hours during labor until delivery.


❑ Antibiotic prophylaxis in patients with a history of anaphylaxis, angioedema, respiratory distress, or urticaria following penicillin or cephalosporin is guided by antibiotic susceptibility testing. If GBS is sensitive to both clindamycin and erythromycin, then clindamycin 900 mg intravenous every 8 hours is recommended for GBS prophylaxis during labor until delivery.[20][21]


❑ If the culture returns resistant to erythromycin, vancomycin 1 gm intravenously every 12 hours is recommended for GBS prophylaxis.


❑ If patient is penicillin allergic, vancomycin is the choice of treatment.


❑Cefazolin 2 gram intravenous loading dose followed by 1 gm every 8 hours may be used in patients without a history of anaphylaxis, angioedema, respiratory distress, or urticaria following penicillin or cephalosporin administration.[20]

Initiating antibiotic prophylaxis greater than 4 hours before delivery is considered to be adequate antibiotic prophylaxis and is effective in the prevention of transmission of GBS to the fetus.[20]
Listeriosis IV ampicillin and gentamicin (for both mother and newborn) *Avoidance of soft cheeses
  • Avoidance of potentially contaminated water and food: See “Food and water safety” in food poisoning.
  • Nationally notifiable condition: Listeriosis must be reported to the local or state health department.[22]
Syphilis Therapy is indicated in the gravida with a positive FTA-ABS of recent onset, and the drug of choice is penicillin. [23] The regimen recommended is the same as in the nonpregnant woman. For early syphilis, a single dose of 2.4 million units of benzathine penicillin G is recommended. Some recommend a follow-up dose 1 week later, particularly in the third trimester. For late-stage syphilis (more than 1 year of duration), three doses are recommended. For the patient allergic to penicillin, treatment with penicillin after oral desensitization is recommended. This should be done in a facility that has appropriate provisions for resuscitation, if needed. [24] *Maternal screening in early pregnancy
  • Nationally notifiable condition: Congenital syphilis and syphilitic childbirth must be reported to local or state health department.[25]
Gonorrhea current recommendations include one of the following regimens:

In addition, treatment for Chlamydia should be administered because of the likelihood of coinfection. Disseminated infection in the newborn requires high-dose treatment, and ophthalmic infection should be treated both locally and systemically.

Prevention of perinatal infection is best accomplished by careful maternal screening and treatment.
Chlamydia ❑ Recommended treatment : The question of maternal screening and prophylactic treatment to prevent neonatal infection is unsettled. As diagnostic studies have become more readily available, screening has become more practical. The decision to routinely screen a prenatal population should probably be based on a determination of the specific population prevalence.
Salmonella chloramphenicol

❑ Alternate antibiotics are ampicillin or amoxicillin

❑ Combination of trimethoprim and sulfamethoxazole is useful for resistant strains but avoided in pregnancy if possible.

Aspirin should be avoided because patients with typhoid are extremely sensitive and severe hypothermia may occur.

❑ Sanitation and hygienic processes and the control of faulty food processing.
Trichomonas vaginalis Vaginal trichomoniasis has adverse pregnancy outcomes, so metronidazole, 2 g orally as a single dose, can be given after the first trimester.
Malaria ❑ Pregnant woman who must travel to an endemic area should take Chloroquine phosphate, 500 mg once a week starting 1 week before the trip and continuing for 6 weeks. This is safe for pregnant women. [26]
Zika virus ❑ Avoidance of travel to ZIKv endemic areas during pregnancy.

❑ The use of N,N-Diethyl-meta-toluamide, which has been recommended in pregnancy to prevent ZIKA infection.

❑ Long sleeves and pants or permethrin-treated clothing.

❑ Use of mosquito nets and window screens if living in or traveling to an endemic area.

❑ If the pregnant woman is living in an endemic area, areas of standing water such as tires, buckets, planters should be eliminated because they are a breeding area for mosquitoes.

❑ All pregnant women and their partners should receive counseling on prevention measures including avoidance of mosquito bites and sexual transmission.

❑ If a couple has a male partner and he travels to an area with ZIKA Virus, they should use condoms or abstain from sexual activity for 6 months (even if there is no symptoms).

❑ If a female travels to an area with risk of ZIKV, condoms or abstinence from sexual activity for 8 weeks (even in the absence of symptoms) is recommended.

❑ If a pregnant patient and her partner travel to or live in an area with Zika virus, condoms should be used each time the couple has sex for the remainder of pregnancy, or they should abstain from sexual activity. [27]

Do's

  • The content in this section is in bullet points.

Don'ts

  • The content in this section is in bullet points.

References

  1. Neu N, Duchon J, Zachariah P (2015). "TORCH infections". Clin Perinatol. 42 (1): 77–103, viii. doi:10.1016/j.clp.2014.11.001. PMID 25677998.
  2. 2.0 2.1 Paquet C, Yudin MH (January 2013). "Toxoplasmosis in pregnancy: prevention, screening, and treatment". J Obstet Gynaecol Can. 35 (1): 78–81. doi:10.1016/s1701-2163(15)31053-7. PMID 23343802.
  3. 3.0 3.1 3.2 Kravetz JD, Federman DG (September 2005). "Prevention of toxoplasmosis in pregnancy: knowledge of risk factors". Infect Dis Obstet Gynecol. 13 (3): 161–5. doi:10.1080/10647440500068305. PMC 1784564. PMID 16126501.
  4. Freij BJ, South MA, Sever JL (June 1988). "Maternal rubella and the congenital rubella syndrome". Clin Perinatol. 15 (2): 247–57. PMID 3288422.
  5. [Centers for Disease Control and Prevention. Three Cases of Congenital Rubella Syndrome in the Post elimination Era: Maryland, Alabama, and Illinois, 2012. MMWR Morb Mortal Wkly Rep. 2013; 62(12): pp. 226–229. url: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6212a3.htm. ], additional text.
  6. Pass RF, Arav-Boger R (2018). "Maternal and fetal cytomegalovirus infection: diagnosis, management, and prevention". F1000Res. 7: 255. doi:10.12688/f1000research.12517.1. PMC 5832908. PMID 29560263.
  7. Kimberlin DW, Lin CY, Sánchez PJ, Demmler GJ, Dankner W, Shelton M, Jacobs RF, Vaudry W, Pass RF, Kiell JM, Soong SJ, Whitley RJ (July 2003). "Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial". J Pediatr. 143 (1): 16–25. doi:10.1016/s0022-3476(03)00192-6. PMID 12915819.
  8. [Julie Johnson, MD, Brenna Anderson, MD, MSc, and Robert F. Pass, MD. Prevention of Maternal and Congenital Cytomegalovirus Infection. Clinical Obstetrics and Gynecology. 2013. url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3347968/], additional text.
  9. 9.0 9.1 Straface G, Selmin A, Zanardo V, De Santis M, Ercoli A, Scambia G (2012). "Herpes simplex virus infection in pregnancy". Infect Dis Obstet Gynecol. 2012: 385697. doi:10.1155/2012/385697. PMC 3332182. PMID 22566740.
  10. Giorgio E, De Oronzo MA, Iozza I, Di Natale A, Cianci S, Garofalo G, Giacobbe AM, Politi S (October 2010). "Parvovirus B19 during pregnancy: a review". J Prenat Med. 4 (4): 63–6. PMC 3279187. PMID 22439064.
  11. 11.0 11.1 11.2 "Recommendations of the U.S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immunodeficiency Virus".
  12. Jamieson DJ, Read JS, Kourtis AP, Durant TM, Lampe MA, Dominguez KL (September 2007). "Cesarean delivery for HIV-infected women: recommendations and controversies". Am J Obstet Gynecol. 197 (3 Suppl): S96–100. doi:10.1016/j.ajog.2007.02.034. PMID 17825656.
  13. Andiman W, Bryson Y, de Martino M, Fowler M, Harris D, Hutto C, Korber B, Kovacs A, Landesman S, Lindsay M, Lapointe N, Mandelbrot L, Newell M, Peavy H, Read J, Rudin C, Semprini A, Simonds R, Tuomala R (April 1999). "The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1--a meta-analysis of 15 prospective cohort studies". N Engl J Med. 340 (13): 977–87. doi:10.1056/NEJM199904013401301. PMID 10099139. Vancouver style error: initials (help)
  14. Hayward K, Cline A, Stephens A, Street L (October 2018). "Management of herpes zoster (shingles) during pregnancy". J Obstet Gynaecol. 38 (7): 887–894. doi:10.1080/01443615.2018.1446419. PMID 29565203.
  15. Heuchan AM, Isaacs D (March 2001). "The management of varicella-zoster virus exposure and infection in pregnancy and the newborn period. Australasian Subgroup in Paediatric Infectious Diseases of the Australasian Society for Infectious Diseases". Med J Aust. 174 (6): 288–92. PMID 11297117.
  16. Daley AJ, Thorpe S, Garland SM (February 2008). "Varicella and the pregnant woman: prevention and management". Aust N Z J Obstet Gynaecol. 48 (1): 26–33. doi:10.1111/j.1479-828X.2007.00797.x. PMID 18275568.
  17. [ Centers for Disease Control and Prevention. 2017 Nationally Notifiable Conditions. https://wwwn.cdc.gov/nndss/conditions/notifiable/2017/. Updated January 1, 2017. Accessed March 22, 2017], additional text.
  18. Chaudhry SA, Koren G (November 2015). "Hepatitis A infection during pregnancy". Can Fam Physician. 61 (11): 963–4. PMC 4642904. PMID 26881283.
  19. 19.0 19.1 Ghulmiyyah LM, Alame MM, Mirza FG, Zaraket H, Nassar AH (2015). "Influenza and its treatment during pregnancy: A review". J Neonatal Perinatal Med. 8 (4): 297–306. doi:10.3233/NPM-15814124. PMID 26836818.
  20. 20.0 20.1 20.2 20.3 20.4 "Group B Streptococcus And Pregnancy - StatPearls - NCBI Bookshelf".
  21. 21.0 21.1 "Committee Opinion No. 485: Prevention of Early-Onset Group B Streptococcal Disease in Newborns: Correction". Obstet Gynecol. 131 (2): 397. February 2018. doi:10.1097/AOG.0000000000002466. PMID 29370038.
  22. [ Janakiraman V. Listeriosis in pregnancy: diagnosis, treatment, and prevention. Rev Obstet Gynecol. 2008; 1(4): pp. 179–85. pmid: 19173022. ], additional text.
  23. [ Centers for Disease Control: Syphilis: CDC recommended treatment schedules. J Infect Dis 134: 97, 1976], additional text.
  24. [ ACOG Educational Bulletin No 245, March 1998, American College of Obstetricians and Gynecologists ], additional text.
  25. [Centers for Disease Control and Prevention. 2017 Nationally Notifiable Conditions. https://wwwn.cdc.gov/nndss/conditions/notifiable/2017/. Updated January 1, 2017. Accessed March 22, 2017. ], additional text.
  26. [ Sever JL, Larsen JN, Grossman JH: Toxoplasmosis. In: Handbook of Perinatal Infections, pp 157–163. Boston, Little, Brown, 1979 ], additional text.
  27. [ Centers for Disease Control and Prevention (CDC). Zika virus prevention. Available at: https://www.cdc.gov/zika/prevention/index.html. Accessed April 24,2017], additional text.


Template:WikiDoc Sources